Intuitive Surgical (NASDAQ:ISRG) Trading Down 0.8%

Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) fell 0.8% during trading on Thursday . The company traded as low as $468.46 and last traded at $478.10. 250,300 shares changed hands during trading, a decline of 83% from the average session volume of 1,512,004 shares. The stock had previously closed at $481.73.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ISRG. The Goldman Sachs Group initiated coverage on Intuitive Surgical in a research note on Thursday, May 30th. They issued a “buy” rating and a $500.00 price target on the stock. Stifel Nicolaus boosted their target price on Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a research note on Friday, July 19th. JPMorgan Chase & Co. increased their price target on shares of Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a research note on Friday, July 19th. Evercore ISI reduced their price objective on shares of Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating for the company in a research report on Friday, July 19th. Finally, BTIG Research upped their target price on shares of Intuitive Surgical from $469.00 to $494.00 and gave the company a “buy” rating in a report on Wednesday, August 28th. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $446.45.

Intuitive Surgical Stock Performance

The stock has a market capitalization of $168.84 billion, a PE ratio of 86.28, a price-to-earnings-growth ratio of 5.43 and a beta of 1.39. The business’s 50-day moving average is $457.57 and its two-hundred day moving average is $416.92.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.24. The business had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The business’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.18 earnings per share. Equities analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, EVP Robert Desantis sold 239 shares of the stock in a transaction on Monday, June 10th. The stock was sold at an average price of $416.60, for a total value of $99,567.40. Following the completion of the transaction, the executive vice president now owns 5,506 shares in the company, valued at $2,293,799.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, EVP Myriam Curet sold 2,818 shares of the business’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total transaction of $1,291,010.34. Following the sale, the executive vice president now owns 298 shares of the company’s stock, valued at approximately $136,522.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Robert Desantis sold 239 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $416.60, for a total value of $99,567.40. Following the completion of the transaction, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at $2,293,799.60. The disclosure for this sale can be found here. In the last three months, insiders sold 51,656 shares of company stock valued at $24,700,644. Corporate insiders own 0.90% of the company’s stock.

Institutional Trading of Intuitive Surgical

Institutional investors have recently bought and sold shares of the company. Advisors Asset Management Inc. grew its position in shares of Intuitive Surgical by 18.1% in the first quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider’s stock valued at $2,945,000 after purchasing an additional 1,129 shares during the last quarter. Public Employees Retirement System of Ohio raised its holdings in shares of Intuitive Surgical by 5.4% in the fourth quarter. Public Employees Retirement System of Ohio now owns 191,283 shares of the medical equipment provider’s stock worth $64,531,000 after acquiring an additional 9,869 shares during the last quarter. HCR Wealth Advisors lifted its position in shares of Intuitive Surgical by 26.3% in the fourth quarter. HCR Wealth Advisors now owns 1,042 shares of the medical equipment provider’s stock valued at $352,000 after acquiring an additional 217 shares in the last quarter. Checchi Capital Advisers LLC boosted its stake in shares of Intuitive Surgical by 2.5% during the fourth quarter. Checchi Capital Advisers LLC now owns 2,875 shares of the medical equipment provider’s stock valued at $970,000 after acquiring an additional 70 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Intuitive Surgical by 0.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 519,807 shares of the medical equipment provider’s stock valued at $175,364,000 after acquiring an additional 4,335 shares during the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.